Welcome to the Porton Newsroom

Porton Pharma Solutions Ltd. (hereinafter “Porton”) is glad to announce that it scored 44 (out of 100) in the 2024 S&P Global Corporate Sustainability Assessment reflecting an improvement of 6 points over the previous assessment, where scores in all the three dimensions getting improved. (CSA Score as of 27/11/2024).

On December 20, 2024, Porton Pharma Solutions Ltd. (hereinafter referred to as “Porton Pharma Solutions” or “Porton”) and Dragon Sail Pharmaceutical (Shanghai) Co., Ltd. (a subsidiary of Guilin Sanjin, hereinafter referred to as “Dragon Sail Pharmaceutical”) formally signed a strategic cooperation agreement in Guilin, southern of China.

Porton Expands GMP Manufacturing and New Modality Services in Shanghai Fengxian Porton Successfully Hosts Ceremony for New Modality Capacity Upgrade Drug Modalities: Innovative Services & Solutions from Porton Pharma

Recently, Porton Pharma Solutions Ltd. ("Porton") announced a strategic partnership with Aojin Life Sciences (Yixing) Co., Ltd. ("Aojin Life Sciences").

Porton was recently selected as a "2024 Exemplary Case for Sustainable Development Among Chinese Listed Companies" by the China Association of Public Companies.

With a Focus on Globalization, Innovative Technology Platforms, and Accelerating Your New Business Opportunities into the Clinic and to the Market.

During the Slovenian government delegation's visit to Shanghai, the Slovenian Consulate in Shanghai and the Shanghai Municipal Commission for Trade Promotion hosted the "China–Slovenia Business and Investment Forum" on November 4th, 2024.

On November 7, 2024, the New Modality Capacity Upgrade Ceremony was successfully held in Fengxian, Shanghai, China. Attendees included Mr. Weng Jun，Vice General Manager，Shanghai Hangzhou Bay Economic & Technological Development Co., Ltd., Mr. Bai Yinchun, COO and Senior Vice President of Porton, Ms. Pi Wei, Vice President and Board Secretary of Porton, Ms. Meng Fan, Deputy General Manager of the Sales & Marketing Center of Porton, and Mr. Xie Lihua, Head of the Synthetic Macromolecules Service Department. Together, they witnessed this significant moment of enhancing the production capacity for new modalities at the Fengxian site.

Porton Pharma has made a major breakthrough in capacity at its GMP manufacturing facility in Fengxian, Shanghai, enhancing its production capabilities significantly.